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The SR family proteins and SR-related polypeptides are important regulators of pre-mRNA splicing. A novel
SR-related protein of an apparent molecular mass of 53 kDa was isolated in a gene trap screen that identifies
proteins which localize to the nuclear speckles. This novel protein possesses an arginine- and serine-rich
domain and was termed SRrp53 (for SR-related protein of 53 kDa). In support for a role of this novel
RS-containing protein in pre-mRNA splicing, we identified the mouse ortholog of the Saccharomyces cerevisiae
U1 snRNP-specific protein Luc7p and the U2AF65-related factor HCC1 as interacting proteins. In addition,
SRrp53 is able to interact with some members of the SR family of proteins and with U2AF35 in a yeast
two-hybrid system and in cell extracts. We show that in HeLa nuclear extracts immunodepleted of SRrp53, the
second step of pre-mRNA splicing is blocked, and recombinant SRrp53 is able to restore splicing activity.
SRrp53 also regulates alternative splicing in a concentration-dependent manner. Taken together, these results
suggest that SRrp53 is a novel SR-related protein that has a role both in constitutive and in alternative
splicing.
Pre-mRNA splicing takes place in the spliceosome, a large
ribonucleoprotein complex that is formed by the small nuclear
ribonucleoprotein particles (U1, U2, U4/U6, and U5 snRNPs)
and numerous non-snRNP splicing factors (reviewed in refer-
ence 36).
The serine- and arginine-rich proteins (SR proteins) are a
highly conserved family of structurally and functionally related
non-snRNP splicing factors with a dual role in splicing, affect-
ing both constitutive and alternative splicing. They have a
modular domain structure consisting of one or two RNA rec-
ognition motifs (RRMs) and a C-terminal domain rich in ar-
ginine and serine residues, termed the RS domain (20). The
RRMs determine RNA binding specificity, whereas the RS
domain, which is extensively phosphorylated, promotes pro-
tein-protein interactions that are essential for the recruitment
of the splicing apparatus and for splice site pairing (61, 67).
The RS domains have been shown to directly contact the
pre-mRNA branch point; thus, RS domains may not solely
function through protein-protein interactions (53). In addition,
the RS domain of SR proteins directs subcellular localization
and determines the nucleocytoplasmic shuttling of individual
SR proteins (10, 27, 39).
The SR family proteins function early in spliceosome for-
mation and are involved in multiple steps of the splicing reac-
tion (59). They facilitate the recruitment of the U1 snRNP
particle to the 5 splice site (18, 33, 35) and also bridge the 5
and 3 splice sites via RS-domain-mediated interactions with
U1 and U2 snRNP-associated proteins (67). The SR family
proteins also participate at later stages of the splicing reaction,
when they facilitate the recruitment of the U4/U6  U5 tri-
snRNP complex (48).
A class of related RS-domain-containing proteins that may
or may not contain RRMs is also involved in splicing regula-
tion and has been termed the SR-protein-related polypeptides
(SRrp) or SR-like proteins (6). The SR-related proteins func-
tion in spliceosome assembly and also participate in the rec-
ognition of exonic splicing enhancers (ESEs), leading to the
activation of otherwise inefficient upstream 3 splice sites (re-
viewed in references 5 and 26). For instance, the SR-related
nuclear matrix proteins SRm160 and SRm300, which contain
RS domains but lack RRMs, mediate interactions between one
or more SR family and/or SR-related protein bound to ESEs
and basal splicing factors, including U1 and U2 snRNP com-
ponents (7). Two human SR-related proteins of 65 and 110
kDa are essential for the recruitment of the tri-snRNP to the
prespliceosomes but not for the maintenance of tri-snRNP
stability (41). Some of the SR-related proteins are structurally
very similar to authentic SR proteins, although they are func-
tionally different. For instance, SRrp86, does not complement
splicing-defective S100 extracts, but it is able to inhibit the
ability of individual SR proteins to activate splicing and also
antagonizes SR proteins in alternative splicing regulation (2,
3). Likewise, two SR-protein-like factors, SRrp40 (also known
as SRp38) and SRrp35, antagonize authentic SR proteins and
regulate alternative splicing (15). Interestingly, specific de-
phosphorylation of SRp38 converts this protein to a general
repressor that inhibits splicing at an early step in M-phase cells
and also during heat shock (55, 56). A recent genome-wide
survey revealed a large complexity of RS-domain-containing
proteins in metazoans with functions not only in pre-mRNA
splicing but also in chromatin remodeling, transcription by
RNA polymerase II, and cell cycle progression (8). Thus, SR-
related proteins may not only be involved in mRNA processing
but have a more complex array of functions in mammalian
cells.
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We have identified and cloned a novel SR-related protein
that contains a domain rich in arginines and serines but lacks
a recognizable RRM. We show that this novel protein, termed
SRrp53 (for SR-related protein of 53 kDa), localizes to the
nuclear speckled domain and interacts with other splicing reg-
ulators, such as Luc7p, a protein that is part of the U1 snRNP
and has a role in 5 splice site recognition in S. cerevisiae (19),
and HCC1, a factor highly homologous to the large subunit of
the U2AF splicing factor (32). We also demonstrate that
SRrp53 is required for the second step of splicing and also
regulates alternative splicing. Taken together, these results
suggest that SRrp53 is a novel SR-related protein that has a
role both in constitutive and in alternative splicing.
MATERIALS AND METHODS
Bioinformatic analysis of SRrp53 and its related homologues. Known protein
domains and motifs were searched for by using Superfamily (23), InterPro (1),
and associated databases. Proteins putatively orthologous to the SRrp53 protein,
found in databases as the Q9DBU6 protein, were identified via reciprocal
BLAST searches.
Cloning and sequencing of mouse and human SRrp53. Mouse and human
versions of SRrp53 were cloned by reverse transcription (RT)-PCR from total
RNA from mouse embryonic stem (ES) cells or human Hep3B cells, respectively.
Total RNA was prepared using Total RNA Isolation Reagent (ABgene) accord-
ing to manufacturer’s specifications. Approximately 5 g of total RNA was used
for the synthesis of first-strand cDNA with SuperScriptII RNase H reverse
transcriptase (Invitrogen), and 10% of the cDNA obtained in each case was used
for PCR amplification. Fragments corresponding to the full-length coding se-
quence of mouse and human SRrp53 were amplified using specific primers that
introduce SpeI and BamHI restriction sites, ligated into the corresponding sites
of pBlueScript SKII, and fully sequenced.
Expression plasmids. The mammalian expression vector pCGT7 used to ex-
press mouse and human SRrp53 has been previously described (10). Transcrip-
tion is driven by the cytomegalovirus enhancer/promoter, and the coding se-
quence begins with an N-terminal epitope tag, MASMTGGQQMG, which
corresponds to the first 11 residues of the bacteriophage T7 gene 10-capsid
protein and is recognized by the T7 tag monoclonal antibody (MAb) (Novagen).
Due to the presence of an internal XbaI site in the SRrp53 cDNA, the amplified
fragments were designed with SpeI and BamHI sites and were subcloned into the
XbaI-BamHI sites of pCGT7. The plasmid expressing hLuc7a was prepared in a
similar way. A fusion of SRrp53 to green fluorescent protein (GFP) was con-
structed by amplification of mSRrp53 with specific primers, and the resulting
PCR product was subcloned as EcoRI-BamHI fragment into pEGFP-C1 (NH2-
terminal tag) (Clontech).
Oligonucleotides. The sequences of the specific primers used for PCR are
available upon request.
Expression and purification of recombinant proteins. Recombinant T7-
SRrp53 was expressed in 293T cells and purified as described elsewhere (D.
Cazalla and J. F. Ca´ceres, submitted for publication). Briefly, 293T cells were
grown to confluence in T150 flasks and transiently transfected with 60 g of
epitope-tagged, full-length SRrp53 expression plasmid and 120 l of Lipo-
fectamine 2000 (Invitrogen) per flask. Forty-eight hours after transfection, cells
were lysed and recombinant protein was purified by anti-T7-agarose affinity
chromatography. The recombinant baculovirus strain expressing His-hnRNP L
was kindly provided by A. Bindereif. Recombinant His-hnRNP L was expresed
in Sf9 cells and purified as described previously (31).
Production and purification of antibodies against SRrp53. Polyclonal anti-
bodies were raised in rabbit against two synthetic peptides that are conserved
between the human and mouse SRrp53 proteins encompassing amino acids 207
to 221 (207EEEAKRRKEEDQATL221) and the last 15 amino acids of the pro-
tein (319LIALRQERLMGSPVA334), which were designated PEP1 and PEP2,
respectively. Animals were injected with these peptides coupled to keyhole
limpet hemocyanin (KLH) and boosted 4 weeks later. To affinity purify antibod-
ies, rabbit serum from the fourth bleed was passed over peptide affinity columns,
which were prepared by coupling 2 mg of peptide to 1 ml of SulfoLink coupling
gel (Pierce) following manufacturer’s protocol. After binding to the different
columns, antibodies were recovered from only the column prepared with PEP2,
suggesting that the animal used did not generate antibodies against PEP1. Poly-
clonal antibodies against HCC1 were raised by injecting a sheep with glutathione
S-transferase fused to amino acids 197 to 227 of HCC1. Specific antibodies
against HCC1 were obtained by affinity purification from the third-bleed serum
over a CNBr-activated Sepharose column (Amersham) covalently bound to an
HCC1 peptide encompassing amino acids 197 to 227.
Cell culture and transfections. HeLa, 293T, and 3T3 cell lines were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal
calf serum and incubated at 37°C in the presence of 5% CO2. HeLa and 293T
cells were transfected with 3 g of DNA and 5 l of Lipofectamine 2000
(Invitrogen) per well in six-well plates or with 15 g of DNA and 45 l of
Lipofectamine 2000 per 10-cm-diameter dish according to manufacturer’s in-
structions.
Indirect immunofluorescence. Cells were fixed and permeabilized for immu-
nofluorescence assays at 24 h after transfection. Fixation was with 4% p-form-
aldehyde in phosphate-buffered saline (PBS) for 15 to 30 min at room temper-
ature, followed by incubation for 10 min in 0.2% Triton X-100 in PBS. Fixed cells
were then incubated for 1 h at room temperature with the first antibody, washed
with PBS, and incubated for 1 h at room temperature with a secondary antibody,
followed by further washes with PBS. The samples were observed on a Zeiss
Axioskop microscope, and the images were acquired with a Photometrics CH250
cooled charge-coupled-device camera by using Digital Scientific Smartcapture
extensions in software from IP Lab Spectrum. MAbs against SC35 (21) were
kindly provided by Xiang-Dong Fu and used in a 1:500 dilution.
Heterokaryon assays. For transient transfections involving interspecies het-
erokaryons, due to the need for higher transfection efficiency, transfection was
carried out by electroporation using 10 g of plasmid DNA per 60-mm-diameter
dish of 70 to 80% confluent cells in the presence of 20 g of carrier DNA.
Transfected HeLa cells were seeded on coverslips, followed by coincubation with
an excess of untransfected mouse NIH 3T3 cells for 3 h in the presence of 50 g
of cycloheximide/ml. The concentration of cycloheximide was then increased to
100 g/ml, and the cells were incubated for an additional 30 min prior to fusion.
Cell fusions were done as described previously (45), and the heterokaryons were
further incubated for 2 h in media containing 100 g of cycloheximide/ml prior
to fixation. Immunofluorescence with the anti-T7 MAb was performed as de-
scribed above, except that DAPI was included at 5 g/ml.
Western blot analysis. Samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto Hy-
bond-P (Amersham) in transfer buffer (25 mM Tris base, 40 mM glycine–20%
methanol) in a Genie Blotter unit (Idea Scientific Company) at 12 V for 1 h.
Membranes were blocked with 5% nonfat dry milk in TBST (20 mM Tris [pH
7.5], 137 mM NaCl, 0.1% Tween 20) for 1 h at room temperature or overnight
at 4°C. Proteins were detected by subsequent incubation with the following
primary antibodies in TBST: anti-SRrp53 at a 1:1,000 dilution, MAb 96 at a 1:500
dilution (for detection of SF2/ASF [25]), MAb 104 for detection of total SR
proteins (49), and sheep polyclonal anti-HCC1 antibody at a 1:100 dilution.
Incubation with secondary antibodies (horseradish peroxidase [HRP]-conjugated
anti-mouse immunoglobulin G [IgG], HRP-conjugated anti-rabbit IgG, and
HRP-conjugated anti-sheep IgG at a 1:10,000 dilution) were carried out for 1 h
at room temperature in TBST containing 5% nonfat dry milk. Five washes with
TBST were done after incubations with each antibody, and immunoreactive
protein bands were detected with the SuperSignal system (Pierce) according to
the manufacturer’s instructions.
Dephosphorylation of SRrp53. Ten micrograms of HeLa nuclear extract (4C
Biotech, Seneffe, Belgium) were dephosphorylated by incubation with 10 U of
calf intestinal alkaline phosphatase (CIAP) (Promega) for 30 min at 37°C in the
provided phosphatase buffer and analyzed by Western blotting.
Two-hybrid analysis. The bait construct used for two-hybrid screening, termed
pGBKT7-SRrp53, was constructed by amplifying a SRrp53 cDNA with specific
primers, and the resulting PCR product was subcloned as EcoRI-BamHI frag-
ment into pGBKT7 (Clontech). pGBKT7-SRrp53 N-term was constructed by
amplification of SRrp53 (amino acids 1 through 164) with specific primers, and
the resulting PCR product was subcloned as EcoRI-SalI fragment into pGBKT7
(Clontech), whereas pGBKT7-SRrp53 C-term was constructed by amplification
of SRrp53 (amino acids 165 to 334) with specific primers, and the resulting PCR
product was subcloned as EcoRI-SalI fragment into pGBKT7 (Clontech). The
constructs used for direct yeast two-hybrid analysis expressing SR proteins as
preys were generated by inserting PCR fragments into plasmid pACT2 (Clon-
tech). In each case, the PCR fragment was purified, digested with the appropriate
restriction enzymes, and ligated to the corresponding sites into the pACT2
vector. The constructs expressing U2AF35, U2AF65, SF1, and U1-70K in pACT2
were a gift from Nick Hastie (16). The vectors and strains provided in the
Matchmaker Two-Hybrid System 3 (Clontech) were used to screen a pretrans-
formed mouse brain Matchmaker cDNA Library (Clontech) following manufac-
turer’s protocols. The construct expressing full-length SRrp53 in pGBKT7 plas-
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mid was used as the bait in the screen. Interactors were considered true two-
hybrid positives if they could activate the three ADE2, HIS3, and MEL1
reporters when cotransformed with pGBKT7-mSRrp53 and were unable to ac-
tivate them when cotransformed with pGBKT7. To directly test for the ability of
two known proteins to interact, the pGBKT7-derived plasmids (expressing the
protein of interest as fusion with GAL4 DNA-DB) and the pACT2-derived
construct (expressing the protein of interest as a fusion with GAL4 AD) were
cotransformed into the AH109 strain. The resulting strains were tested for their
ability to activate reporters as described above.
IP. For immunoprecipitation (IP), 293T cells that were either transfected with
a construct expressing the protein of interest or mock transfected were resus-
pended in 800 l of IP buffer (50 mM Tris [pH 7.5], 300 mM NaCl, 5 mM EDTA,
0.5% Triton X-100, 1 mM dithiothreitol, 1 protease inhibitor cocktail) and
were then incubated for 30 min at 4°C with continuous mixing on a rotary mixer.
The IP extract was centrifuged at 12,000  g for 20 min at 4°C, after which the
pellet was discarded.
To 200 l of supernatant (IP extract), 1 l (100 ng) of anti-T7 tag MAb
(Novagen) or 10 l of either immune or preimmune serum and 20 l of protein
A or G (Amersham) were added. The IP extract was then incubated at 4°C for
2 h with continuous rotation. IP reactions were then washed four times with the
IP buffer and once with PBS. In some cases, after the last wash, beads were
treated with 50 g of RNase A/ml for 10 min at 4°C. After RNase A treatment,
beads were resuspended in 40 l of loading buffer (50 mM Tris [pH 7.5], 10%
glycerol, 0.05% SDS, 2.5% -mercaptoethanol) and boiled for 10 min. For
Western blot analysis of immunoprecipitated proteins, 10 l of sample was used.
Immunodepletion of HeLa nuclear extracts. For immunodepletion of HeLa
nuclear extracts, 200 l of the extract (4C Biotech) was first brought to 1 M KCl
and then incubated with beads with coupled antibodies for 2 h at 4°C in Mobi-
columns (MOBITEC) on a rotating wheel. After two rounds of depletion were
completed, the depleted nuclear extract was centrifuged at 13,000 rpm at 4°C for
5 min in a microcentrifuge and then dialyzed against two changes of buffer D
(20 mM HEPES [pH 8], 20% glycerol, 0.2 mM EDTA, 0.1 M KCl, 1 mM
dithiothreitol, 0.015% NP-40). After dialysis, the depleted nuclear extract was
aliquoted and stored at 80°C for later use. The extent of depletion was calcu-
lated by comparison of the depleted extracts with untreated extract in SDS-
PAGE.
In vitro splicing assays. Labeled transcripts were prepared in the presence of
an RNA CAP structure analog [m7G(5) ppp(5)G] (New England Biolabs) and
[-32P]GTP (PerkinElmer) as previously described (50). Adenovirus major late
(AdML) substrate was linearized with HincII and transcribed with SP6 RNA
polymerase (Ambion). The Fushi tarazu (Ftz) pre-mRNA (47) was linearized
with XhoI and transcribed with T7 RNA polymerase. Transcripts were gel
purified. Standard conditions were used for the splicing reactions (42). In brief,
splicing was carried out in 25-l reactions containing 3.2 mM MgCl2, 1 mM ATP,
20 mM creatine phosphate, 3% polyvinyl alcohol, 30% nuclear extracts, or 45%
immunodepleted or mock-depleted nuclear extracts, complemented with buffer
D with 0.1 M KCl. Reactions were incubated at 30°C for 1 h, and then RNAs
were purified by proteinase K treatment, phenol-chloroform extraction, and
precipitation. Spliced products were separated by electrophoresis on 14% dena-
turing polyacrylamide gels in Tris-borate-EDTA buffer and exposed to Hyper-
film. Immunodepleted extracts were complemented with either buffer D with 0.1
M KCl or T7-SRrp53 and assayed for splicing activity as described above.
In vivo splicing. Transfections of HeLa cells and purification of total RNA
were done as previously described (12). Briefly, 1 g of expression plasmid was
cotransfected with 2 g of the adenovirus E1A reporter plasmid pMTE1A (71).
Approximately 24 h after transfection, RNA was extracted using the Total RNA
isolation reagent (ABgene) following the manufacturer’s instructions. Total
RNA was analyzed by RT-PCR with Superscript II reverse transcriptase (In-
vitrogen) and AmpliTaq DNA polymerase (Roche) as previously described (65).
E1A mRNA detection was carried out with the 5-end-labeled exon 1 forward
primer 5-GTTTTCTCCTCCGAGCCGCTCCGA-3 and the exon 2 reverse
primer 5-CTCAGGCTCAGGTTCAGACACAGG-3. Amplified products were
separated by urea-PAGE, detected by autoradiography, and quantified by Phos-
phoImage analysis.
RESULTS
Identification and cloning of SRrp53. We used a gene trap
screen approach in mouse cells in order to identify novel nu-
clear proteins that localize to the nuclear speckles, since this is
diagnostic of their involvement in RNA processing. We used a
promoterless and ATG-less -geo construct (pGT) and as-
sayed for the subcellular location of the resultant fusion gene
product (62). Integration of the gene trap -geo construct into
the mouse genome ensured that the tagged protein was ex-
pressed at endogenous levels and in the correct temporal fash-
ion. The sequence of the trapped gene was identified by 5
rapid amplification of cDNA ends from the fusion transcript
(60).
This strategy yielded an insertion mutation in a novel SR-
related protein. We cloned and sequenced the full-length
mouse gene that matches a RIKEN cDNA clone: 1200013F24
(sequence accession numbers AK004742 and NM_025822).
The protein encoded by this gene contains 334 amino acids and
includes an amino-terminal domain rich in RS dipeptides and
serine-rich regions, followed by a bipartite nuclear targeting
sequence between amino acids 214 through 230 that coincides
with a helical region predicted to form coiled coil (amino acids
180 through 237), a domain that often mediates protein-pro-
tein interactions. No homology to any other known protein
motifs was found in the carboxy-terminal half of the protein.
Based on experiments described below, we termed this novel
SR-related protein SRrp53. Good candidate orthologues for
mouse SRrp53 exist in vertebrates such as Homo sapiens and
Xenopus laevis (Fig. 1B) but seem to be absent in several other
organisms, including fully sequenced organisms such as Dro-
sophila melanogaster, Caenorhabditis elegans, Arabidopsis thali-
ana, Saccharomyces cerevisiae, and Schizosaccharomyces pombe
(data not shown).
SRrp53 subcellular localization and nucleocytoplasmic
shuttling. Northern blot analysis showed that SRrp53 is widely
yet differentially expressed across a variety of adult mouse
tissues (data not shown). We generated antibodies against a
C-terminal peptide that is conserved between the human and
mouse protein. Western blot analysis with this peptide anti-
body detected a band that migrates with an apparent molecular
mass of 53 kDa in nuclear and S100 extracts (Fig. 2A). A band
of higher molecular mass migrating at approximately 66 kDa
was also observed. Both bands were immunoprecipitated with
the anti-SRrp53 antibody, and mass spectrometry analysis of
the 66-kDa band eluted from a gel identified this slower mi-
grating protein as hnRNP L (46). The identity of SRrp53 was
also confirmed by mass spectrometry analysis (data not
shown). The deduced amino acid sequence of SRrp53 pre-
dicted a protein of 334 amino acids with a calculated molecular
mass of approximately 38.66 kDa. Presumably, potential phos-
phorylation of the serine residues in the RS domain of the
protein accounts for its anomalous migration at 53 kDa on
SDS-PAGE. Similar disparities between predicted molecular
mass and observed migration on SDS-PAGE have been re-
ported for other RS domain-containing proteins, including
SRrp86 and SRp75 (3, 70). The phosphorylation of SRrp53
was confirmed by treatment of nuclear extracts with CIAP and
Western blot analysis of the treated extracts (Fig. 2A). Western
blot analysis of recombinant His-hnRNP L purified from bac-
ulovirus-infected cells and recombinant T7-SRrp53 purified
from 293T cells also showed that the antibodies raised against
the synthetic peptide can recognize both proteins (Fig. 2B).
Taken together, these results indicate that the -SRrp53 anti-
body recognizes SRrp53 and hnRNP L.
Localization of the -geo-SRrp53 fusion protein expressed
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in the gene-trapped mouse ES cells indicated that endogenous
SRrp53 could localize to the nuclear speckles (data not
shown). We showed that a GFP-tagged version of full-length
SRrp53 localized exclusively to the nucleus, with a typical
speckled pattern in transiently transfected HeLa cells. Further-
more, GFP-SRrp53 colocalizes with the SR protein SC35 in
nuclear speckles (Fig. 3A). Identical results were obtained
when HeLa cells were transfected with a construct expressing
FIG. 1. (A) Amino acid sequence of mouse wild-type SRrp53 is shown. The RS domain is in white with a black background. (B) Human SRrp53
is shown aligned by the ClustalW method with the corresponding proteins from Mus musculus (mm), Rattus norvegicus (rat), Gallus gallus (chicken
[gg]), X. laevis (xl), and Oryzias latipes (medaka fish [ol]). Identical residues are shown on a black background, residues conserved in 80% of the
analyzed sequences are shown in a dark grey background, and residues conserved in 60% of the analyzed sequences are shown in a light grey
background. Gaps are shown by dashed lines.
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a T7 epitope-tagged version of wild-type SRrp53 (data not
shown). Arrest of transcription by RNA polymerase II inhibi-
tors, such as actinomycin D, causes speckles to become en-
larged and rounded up (reviewed by Spector [58]). In the
presence of actinomycin D, both the endogenous and tran-
siently transfected SRrp53s relocalized to larger and fewer
speckles, which is typical of splicing factors (Fig. 3B and data
not shown).
It has been shown that many nuclear proteins involved in
RNA metabolism, such as hnRNP proteins (17) and a subset of
SR proteins (11), shuttle between the nucleus and the cyto-
plasm. We used transient transfection in conjunction with in-
terspecies heterokaryons to assay for the nucleocytoplasmic
shuttling of SRrp53 (Fig. 3C). HeLa cells were transfected with
an epitope-tagged SRrp53 cDNA and then were fused to
mouse NIH 3T3 cells to form heterokaryons. Prior to fusion,
the cells were treated with cycloheximide so that no further
protein synthesis could take place in the heterokaryons. At 2 h
postfusion, the cells were fixed and stained to examine the
distribution of the tagged proteins by immunofluorescence mi-
croscopy with a MAb directed against the epitope tag. To
distinguish the human and mouse nuclei, the cells were stained
with DAPI (4,6-diamidino-2-phenylindole), which gives a
characteristic staining of intranuclear bodies in the mouse nu-
clei. Detection of the tagged protein—originally expressed in
the human cells—within the mouse nuclei in the heterokaryons
is indicative of shuttling (and therefore of nuclear export).
Analysis of heterokaryons formed between human cells ex-
pressing T7-tagged SRrp53 and mouse acceptor cells clearly
showed that the epitope-tagged SRrp53 was detectable in both
nuclei (Fig. 3C). These data indicate that SRrp53 shuttles
between the nucleus and the cytoplasm, suggesting that this
protein could have a role in postsplicing mRNA processing.
SRrp53 interacts with splicing factors. In order to identify
interacting proteins, yeast two-hybrid screens were carried out
with the full-length sequence of SRrp53 as bait. In support for
a role of SRrp53 in pre-mRNA splicing, we identified Luc7p
and HCC1 as interacting proteins (Fig. 4A and B). An inter-
action with the DNA binding protein SON, which contains a
stretch of RS dipeptides similar to the ones identified in SR
proteins (68), was also detected. We confirmed these two-
hybrid interactions by testing that SRrp53 used as a bait di-
rectly interacted with HCC1 and that Luc7p and SON fused to
an activation domain (Fig. 4A).
The LUC7 gene was identified in yeast in a synthetic lethal
screen with the nuclear cap binding complex (CBC) and was
shown to be a component of the U1 snRNP and to be involved
in 5site selection (19). The Luc7 gene seems to have under-
gone duplications several times during evolution, and three
Luc7 genes (Luc7A, -B, and -C) were present in the human
genome. Interestingly, human Luc7p does not seem to be a
stable U1 snRNP component in humans (28). Human Luc7A/
CROP (for cisplatin resistance-associated overexpressed
protein) was isolated as an overexpressed gene in a cispla-
tin-resistant cell line (43); it contained arginine-serine and
arginine-glutamic acid (RE) repeat sequences characteristic of
SR and SR-related proteins and two zinc finger motifs (Zn).
HCC1, a 64-kDa nuclear autoantigen that harbors splicing
factor motifs, was originally identified with an antibody from a
hepatocellular carcinoma patient (32). It comprises two related
proteins, most likely generated by alternative splicing, termed
HCC1.3 and HCC1.4, which differ by 6 amino acids. HCC1
localizes to the nuclear speckles and contains an N-terminal
RS domain and three RRMs. The modular structure of HCC1
and the presence of an octapeptide sequence, the RS-ERK
motif, within its RS domain is reminiscent of the large subunit
of the U2AF splicing factor U2AF65.
All the identified interacting proteins contained an RS do-
main, and in every case, the portion of the interacting protein
that was expressed as a fusion with the activating domain of the
GAL4 transcription factor contained at least part of this do-
main (Fig. 4). This fact suggested that the interactions ob-
served were mediated directly by these RS domains. We show
that, except for HCC1, all the other identified factors showed
positive interaction with the RS domain of SRrp53 (Fig. 4A).
Surprisingly, the C terminus of SRrp53 seemed to mediate the
interaction with HCC1. This is reminiscent of the interaction
described between U2AF65 and U2AF35, which is not medi-
ated by their RS domains (72).
A group of RS domain-containing proteins that have a well-
characterized role in splicing was tested for their ability to
interact with SRrp53. The SR proteins SF2/ASF and SRp40
were able to interact with full-length SRrp53 (Fig. 4C). These
FIG. 2. Characterization of SRrp53 by Western blot analysis.
(A) The amounts of 10 g of nuclear extract (lane 1), 10 g of
CIAP-treated nuclear extract (lane 2), and 50 g of S100 extract (lane
3) were analyzed by Western blotting with anti-SRrp53-B4 (fourth
bleed) antibody. Protein size markers (molecular weights [MW]) are
indicated to the left. (B) The amounts of 20 ng of recombinant His-
hnRNP L purified form baculovirus-infected Sf9 cells (lane 1) and 20
ng of T7-SRrp53 purified from 293T cells (lane 2) were analyzed as
described for panel A. Protein size markers are indicated to the left.
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interactions seemed to be mediated by their RS domain, since
both SF2/ASF and SRp40 interact with the N terminus of
SRrp53 but not with its C terminus. In contrast, no interaction
was detected with SRp55, SRp20, 9G8, or SRp30c. These data
indicate that SRrp53 has specificity for SF2/ASF and SRp40
RS domains and that it does not simply bind to any RS domain.
SRrp53 also interacts with the small subunit of the U2AF
splicing factor, U2AF35, and this interaction is mediated by its
RS domain. In contrast, no interactions were detected with the
large subunit, U2AF65, nor with the U1 snRNP-specific U1-
70K protein or the splicing factor SF1 (Fig. 4C). Furthermore,
the fact that SRrp53 interacts with U2AF35 suggests a possible
role for this novel SR-related protein in 3 splice site selection.
SRrp53 interacts with Luc7p and with HCC1 in cultured
cells. We confirmed the two-hybrid interactions of SRrp53
with Luc7p, SF2/ASF, and HCC1 by coimmunoprecipitation
experiments from human 293 cell extracts. An epitope-tagged
T7-hLuc7A was transiently expressed in 293T cells, and ex-
tracts immunoprecipitated with a MAb against the T7 tag were
revealed with an anti-SRrp53 antibody. As shown in Fig. 5A,
hLuc7A was able to pull down SRrp53. Furthermore, this
interaction is not RNA-mediated, since treatment with RNase
FIG. 3. (A) HeLa cells were transfected with a plasmid encoding GFP-SRrp53 and fixed 24 h posttransfection. Endogenous SC35 was detected
by indirect immunofluorescence with an anti-SC35 MAb and fluorescein isothiocyanate (FITC)-conjugated secondary antibody. Images were
superimposed to reveal sites of overlap in yellow (Merge). (B) Effect of transcription inhibition on the subcellular localization of SRrp53. HeLa
cells were transfected with a plasmid encoding T7-SRrp53; cells were then incubated with actinomycin D (AcTD) plus cycloheximide for 3 h and
fixed at 24 h posttransfection. The localization of the expressed proteins was determined by indirect immunofluorescence with anti-T7 MAb and
FITC-conjugated secondary antibody. (C) Analysis of nucleocytoplasmic shuttling of SRrp53 by transient expression in interspecies heterokaryons.
The SRrp53 protein was transiently expressed in HeLa cells, and 24 h posttransfection, the cells were treated with cycloheximide and subsequently
fused with mouse NIH 3T3 cells in the presence of polyethylene glycol to form heterokaryons. The cells were further incubated for 2 h in the
presence of cycloheximide, followed by fixation. The localization of the epitope-tagged proteins in the heterokaryons was determined by indirect
immunofluorescence with anti-T7 MAb and FITC-conjugated secondary antibody (left panel). The cells were simultaneously incubated with DAPI
for differential staining of human and mouse nuclei within heterokaryons (center panel). The arrows indicate the mouse nuclei within human-
mouse heterokaryons. Phase-contrast images of the same heterokaryons are shown (right panel).
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decreased, but did not abolish, this interaction. Furthermore,
SF2/ASF was detected in an immunoprecipitate from 293T
cells with anti-SRrp53 antibodies (Fig. 5B). Again, RNA did
not mediate this interaction. Finally, HCC1 was also detected
in immunoprecipitate with -SRrp53 antibodies, even when
the immunoprecipitate was treated with RNase, suggesting
that this interaction is not mediated by RNA (Fig. 5C). Taken
together, these results confirm the interaction data obtained
with the yeast two-hybrid system and conclusively demonstrate
that this novel SR-related protein functionally interacts with
splicing factors.
SRrp53 is required for the second catalytic step of pre-
mRNA splicing. Nuclear extracts were depleted of SRrp53 with
specific antibodies and then tested for the ability to splice
AdML- and Ftz-derived pre-mRNA substrates. Following two
rounds of depletion with a specific antibody at 1 M KCl, the
concentration of SRrp53 in the extract was reduced by approx-
imately 99%, whereas it was not significantly depleted with the
FIG. 4. SRrp53 interacts with RS-domain-containing proteins in a yeast two-hybrid system. (A) Reconstitution of two-hybrid interactions found
in a yeast two-hybrid screen. The center panel shows growth on selective media without adenine, and the right panel shows activation of the MEL1
reporter. In each panel, yeast cells were cotransformed with each of the prey plasmids (pGAD) isolated from the screen (indicated above the gels)
and bait vectors expressing either full-length SRrp53 (first row), the N-terminal half of the protein comprising the RS domain (second row), the
C-terminal half of the protein (third row), or the empty vector (fourth row). (B) A diagram illustrating the structure of each interactor. The
portions of each protein covered by selected clones are indicated by bars (with the N- and C-terminal amino acid numbers shown). (C) Interactions
between wild-type or mutant versions of SRrp53 and different splicing factors. Yeast cells were cotransformed with prey plasmids encoding
different splicing factors (indicated above) with bait vectors expressing either full-length SRrp53 (first row), the N-terminal half of the protein
comprising the RS domain (second row), the C-terminal half of the protein (third row), or the empty vector (fourth row) and were tested for their
ability to grow in the absence of adenine. In all cases, activation of the ADE3 reporter correlated with activation of the MEL1 reporter (data not
shown).
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preimmune antibody (Fig. 6A, left panel). The hnRNP L pro-
tein that cross-reacts with anti-SRrp53 antibodies was code-
pleted with SRrp53 from these extracts. Moreover, the relative
amount of individual SR proteins remains unchanged in HeLa
extracts immunodepleted of SRrp53, as revealed by Western
blot analysis using MAb 104 (Fig. 6A, right panel). We found
that treatment with preimmune serum results in a relative
accumulation of intermediate products and a lower yield of
spliced product compared to the untreated extracts. These
effects may, however, be related to nonspecific (e.g., dilution)
effects of the depletion procedure. Nevertheless, preimmune
depleted extracts were able to carry out splicing, as it was
revealed by the accumulation of spliced product. In contrast,
no accumulation of spliced product was observed with SRrp53-
depleted extracts with both substrates analyzed, indicating that
this protein is essential for splicing (Fig. 6B). The second step
of the splicing reaction, which generates released intron-lariat
and ligated exons, was preferentially affected by SRrp53 de-
pletion under these conditions, indicating that this protein
plays a role in this step. More importantly, addition of recom-
binant SRrp53 to the immunodepleted HeLa extract restored
splicing activity (Fig. 6C, left panel). By contrast, complemen-
tation of the depleted extracts with recombinant hnRNP L, the
cross-reacting band observed on panel A, did not restore splic-
ing activity (Fig. 6C, right panel), in accordance with previous
results, indicating that hnRNP L has no activity in constitutive
splicing (31). Furthermore, individual SR proteins that interact
with SRrp53 (SF2/ASF) or that show no interaction (SRp20)
were not able to complement an extract lacking SRrp53 (Fig.
6C, right panel). Taken together, these results show that the
block in the second step of splicing is due to the removal of
SRrp53, demonstrating that SRrp53 is a second-step splicing
factor.
SRrp53 can regulate alternative splicing in vivo. We sought
to investigate the role of SRrp53 in the regulation of alterna-
tive splicing in vivo. To this end, we overexpressed epitope-
tagged SRrp53 and assayed changes in the patterns of alter-
native splicing of an adenovirus E1A splicing pre-mRNA that
undergoes alternative splicing through the use of three alter-
native 5 splice sites. In agreement with previous results, wild-
type SF2/ASF strongly activated the 13S 5 splice site (12, 65,
66). In contrast, increased expression of SRrp53 resulted in
activation of the most distal 5 splice site, giving rise to the 9S
isoform, as observed for hnRNP A1 (12, 69). However, the
strongest effect of SRrp53 overexpression on E1A alternative
splicing was in the production of the 11S isoform, which in-
volves selection of the most 5-proximal 13S splice site and the
removal of an additional 216-nucleotide intron located down-
stream of the 9S splice site (Fig. 7A,B). This splicing event
requires the activation of a weak 3 splice site (22); thus,
SRrp53 may be influencing 3 splice site activation. Interest-
ingly, it was shown that SF2/ASF, and also SC35, binds to a
bidirectional purine-rich splicing enhancer located just up-
stream of the 12S 5 splice site and activate the 216-nucleotide
intron 3 splice site (9). Quantitation of the relative use of the
E1A splice sites upon overexpression of the different proteins
is shown in Fig. 7C. As described above, SRrp53 interacts with
a subset of SR proteins, such as SF2/ASF and SRp40. There-
fore, the selection of the distal 9S 5 distal splice site by SRrp53
could result from the repression of the activity of SR proteins,
such as SF2/ASF, which promotes the use of the proximal
alternative 5 splice site. Furthermore, the appearance of the
11S isoform could reflect the activity of SRrp53 in 3 splice site
selection, in this case, cooperating with the interacting protein
SF2/ASF.
Taken together, these results suggest that SRrp53 is a novel
SR-related protein that has a role in both constitutive and
alternative splicing.
DISCUSSION
Using a gene trap approach, we have identified a novel
RS-containing protein that localizes to the nuclear speckles.
Three independent avenues suggest that SRrp53 has a role in
pre-mRNA splicing. First, the presence of an RS domain,
which is diagnostic of factors involved in pre-mRNA splicing,
and more generally in RNA processing, lends support to this
conclusion. Second, two-hybrid analysis and IP-Western assays
FIG. 5. SRrp53 interacts with splicing factors in cultured mamma-
lian cells. (A) IP assays with T7-hLuc7a are shown. Extracts prepared
from 293T cells either transiently transfected with a plasmid encoding
T7-hLuc7a (lanes 2 and 3) or mock transfected (lane 4) were incubated
with anti-T7 antibody bound to Sepharose beads (Novagen). The
bound proteins were separated on an SDS–10% polyacrylamide gel
and analyzed by Western blotting with anti-SRrp53B4 antibody. Al-
ternatively, the immunoprecipitate was treated with RNase before
loading on the gel (lane 3). Lane 1 was loaded with 2% of the amount
of extract used for each IP. (B) Extracts prepared from 293T cells were
incubated with either anti-SRrp53B4 antibody (lanes 2 and 3) or pre-
immune serum (lane 4) bound to Sepharose beads and analyzed as
described for panel A. The blot was probed with MAb 96 antibody,
which recognizes SF2/ASF (25). Alternatively, the immunoprecipitate
was treated with RNase before loading on the gel (lane 3). Lane 1 was
loaded with 2% of the amount of extract used for each IP. (C) The
interaction between SRrp53 and HCC1 was analyzed as described for
panel B. The blot was probed with a polyclonal antibody raised in
sheep, which specifically recognizes HCC1.
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have shown that SRrp53 interacts with different proteins that
have either potential or clearly defined functions in splicing.
Third, by using in vivo and in vitro splicing assays, SRrp53 was
shown to be functionally involved in splicing. Furthermore,
nuclear extracts immunodepleted of this protein are unable to
perform the second step of splicing in vitro, suggesting that this
protein is necessary for this step.
The development of protocols that allowed an improved
purification of spliceosomes coupled with advances in mass
spectrometry analyses of complex mixtures has allowed the
identification of the protein composition of the spliceosome
(34 and references therein). Interestingly, SRrp53 is not
present in any of these preparations, and together with its
loose association with snRNP particles (data not shown), it is
suggestive of a transient association of this SR-like protein
with the splicing machinery.
Expression and subcellular localization of SRrp53. The
-geo-SRrp53 fusion protein localized to nuclear speckles in
the gene-trapped mouse ES cell (data not shown), and a tran-
siently expressed epitope-tagged version of SRrp53 confirmed
this localization and also showed colocalization with SC35 in
splicing speckles. This is not surprising, since the RS domain of
certain SR proteins has been shown to be necessary and suf-
ficient for targeting these factors to nuclear speckles (10, 27,
39). Several proteins that participate in pre-mRNA splicing in
the nucleus have been shown to travel to the cytoplasm with
the spliced mRNA. For some of them, cytoplasmic functions
have been described. For instance, members of the hnRNP
family of proteins have been reported to regulate cytoplasmic
events like mRNA localization, translation, and mRNA turn-
over (reviewed in reference 57). We have previously demon-
strated that a subset of SR proteins shuttle continuously from
the nucleus to the cytoplasm, an activity which is reminiscent of
what is observed with certain hnRNP proteins (11, 17). Thus,
shuttling SR proteins may have roles not only in nuclear pre-
mRNA splicing but also in mRNA transport and/or in some
cytoplasmic events. Indeed, shuttling SR proteins have been
shown to facilitate mRNA export (30), to mediate RNA sta-
bility (38), and to be involved in translational regulation (51).
Moreover, SR proteins have been found to strongly enhance
nonsense-mediated decay, and this activity requires the pres-
ence of the RS domain but des not correlate with nucleocyto-
plasmic shuttling (75). The finding that this novel SR-related
protein, SRrp53, shuttles continuously from the nucleus to the
cytoplasm suggests that it may also be involved in cytoplasmic
functions.
The role of SRrp53 in pre-mRNA splicing. The RS domain
is a distinctive feature of SR family proteins and is also present
in SR-related proteins. RS domains have been implicated in
both protein-protein and protein-RNA interactions (67); re-
FIG. 6. Effect of SRrp53 immunodepletion on pre-mRNA splicing in vitro. (A) The extent of SRrp53 depletion from HeLa nuclear extracts
(NE) was assayed by Western blot analyses with an anti-SRrp53 antibody in serial dilutions of untreated extracts (lanes 1 through 5), extracts
depleted with anti-SRrp53B4 antibody (lane 6), or preimmune-serum-depleted extracts (lane 7) (left panel). The profile of SR proteins was not
affected by SRrp53 immunodepletion (right panel). (B) Effect of immunodepletion of SRrp53 on pre-mRNA splicing is shown. AdML pre-mRNA
(lanes 1 and 2) or Ftz pre-mRNA (lanes 3 and 4) was incubated in depleted (lanes 1 and 3) or mock-depleted (lanes 2 and 4) nuclear extracts.
Positions of splicing intermediates and products are indicated to the right. (C) Ftz pre-mRNA substrate was incubated in mock-depleted (lane 1)
or SRrp53-depleted (lanes 2 through 4) nuclear extracts complemented with buffer (lanes 1 and 2) or 100 ng (lane 3) or 300 ng (lane 4) of
T7-SRrp53 (left panel). Positions of splicing intermediates and products are indicated to the right. Ftz pre-mRNA substrate was incubated in
mock-depleted (lane 1) or SRrp53-depleted (lanes 2 through 5) nuclear extracts complemented with buffer (lanes 1 and 2), hnRNP L (lane 3),
SF2/ASF (lane 4), or SRp20 (lane 5) (right panel).
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viewed in reference 24). We have shown that the RS domain of
SRrp53 mediates protein-protein interactions with other RS-
domain-containing proteins in a yeast two-hybrid assay and in
cultured mammalian cells. However, this protein-protein inter-
action profile is different from that reported for other RS-
domain-containing proteins. For example, SF2/ASF and SC35
can both interact with U1-70K and U2AF35 but not with
U2AF65 (67). In contrast, the SR protein p54 interacts with
SF2/ASF and U2AF65 but shows no interaction with either
U1-70K or U2AF35 (73). Similarly, Sip1, an SR-like protein
initially identified in a two-hybrid screen with SC35, interacts
with several SR proteins but also with U1-70K and U2AF65,
proteins that are associated with 5 and 3 splice sites, respec-
tively (74). Here, we show that SRrp53 interacts with SF2/ASF
and U2AF35 but does not interact with U1-70K or U2AF65.
This finding suggest that SRrp53 is not directly mediating in-
teractions between components at the 5 and 3 splice sites but
rather interacts with components of the 3 splice site, suggest-
ing that it might have a role in 3 splice site selection. More-
over, these RS-mediated interactions showed a certain degree
of specificity, since SRrp53 interacts only with two out of six
members of the SR family of proteins that were tested. Inter-
estingly, SRrp53 also interacts with the U2AF65-related factor
HCC1 in the yeast two-hybrid system and in cell extracts.
Although a role for HCC1 in constitutive splicing is unclear, it
can be speculated that its function could be similar to that of
U2AF65, since it is structurally related to this factor (32). If this
were the case, SRrp53 could facilitate the interaction between
U2AF35 and HCC1. Moreover, several factors related to
U2AF35 have been characterized in mammalian cells (54, 63),
suggesting the existence of multiple U2AF-like complexes.
A role for SRrp53 in the second step of pre-mRNA splicing.
During the second step of pre-mRNA splicing, the first exon
and lariat intermediate are joined to form the mRNA. In yeast,
four proteins have been shown to function exclusively in the
second step of pre-mRNA splicing, namely, Prp16, Prp17,
Prp18, and Slu7, whereas Prp8 functions in both steps of the
splicing reaction (reviewed by Umen and Guthrie [64]). Al-
FIG. 7. SRrp53 can regulate 5 splice site selection in vivo. In vivo splicing analyses were performed with HeLa cells transiently cotransfected
with an adenovirus E1A reporter plasmid and expression plasmids encoding for either mouse SRrp53, hnRNP A1 or SF2/ASF. (A) Diagram of
the E1A reporter gene is shown. The alternative 5 splice sites and splicing events that generates 13S, 12S, and 9S mRNAs are shown schematically.
The location of the exon primers used for RT-PCR analysis is shown. (B) HeLa cells were transiently cotransfected with the adenovirus E1A
reporter plasmid and the expression constructs for each of the proteins indicated above the gel or the parental plasmid (Control). RNA was
harvested at 24 h posttransfection and analyzed by RT-PCR with a labeled forward primer, denaturing PAGE, and autoradiography as described
in Materials and Methods. The positions of the unspliced pre-mRNA and of 13S, 12S, and 9S spliced mRNAs are indicated to the right. The 10S
and 11S isoforms (*) did not arise from competition between alternative 5 splice sites. (C) Quantitation of E1A mRNA isoforms in transfected
cells is shown. The relative amounts of 13S, 12S, and 9S E1A mRNAs were calculated from the data given in panel B by using a phosphorimager,
and the percentage of each isoform is shown. Each experiment was repeated four times, and the data represent averages, with bars indicating
standard errors.
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though most mechanistic studies dealing with the second step
of splicing have been carried out in yeast, human homologs of
the second step factors Prp16, Prp17, and Prp18 have been
functionally characterized (4, 29, 40, 76). Prp22, a member of
the DExH-box family of proteins, is involved in the second step
of splicing and also plays a role in the release of spliced mRNA
(52). Interestingly, the human homolog of Prp22, designated
HRH1 (for human RNA helicase 1), contains an RS domain
and was shown to interact with members of the SR protein
family through its RS domain (44). Human Slu7 is a second-
step splicing factor that functions by restructuring the spliceo-
some between the catalytic steps of splicing (13, 14).
Here, we show that HeLa nuclear extracts depleted of
SRrp53 are unable to perform the second step of splicing. A
66-kDa protein that cross-reacts with anti-SRrp53 antibodies
was identified as hnRNP L and was codepleted with SRrp53
from these extracts. However, we were able to restore splicing
activity by complementing the depleted extracts with recombi-
nant SRrp53. It had already been shown that extracts immu-
nodepleted of hnRNP L were active in general pre-mRNA
splicing (31). This experiment clearly shows that the block in
the second step of splicing was due to the removal of SRrp53.
Thus, this novel SR-related protein that interacts with factors
involved in 3 splice site selection has a clear role in the second
step of pre-mRNA splicing. It remains possible that the tran-
sient association of SRrp53 with the spliceosome facilitates the
remodeling of the spliceosome between steps I and II. Work
from different labs indicates that the 3 splice site is recognized
de novo before the second step of splicing takes place (refer-
ences 37 and 64 and references therein). Considering the in-
teractions observed between SRp53 and U2AF35 and between
SRrp53 and HCC1, a U2AF65-like factor, it is tempting to
speculate a role for SRrp53 in the recognition of the 3 splice
site during the second step of splicing. Further experimenta-
tion will be required to test this hypothesis.
SRrp53 regulates alternative splicing. We have also shown
that SRrp53 regulates alternative splicing in vivo. It promotes
selection of the distal 5 splice site in the adenovirus E1A
pre-mRNA, resembling the activity shown by hnRNP A1 but
more importantly, it also promotes the appearance of the 11S
isoform. It is possible that the effect of SRrp53 in the selection
of the distal 5 splice site in the E1A pre-mRNA results from
the titration of interacting SR proteins, such as SF2/ASF and
SRp40. Furthermore, the appearance of the 11S isoform could
reflect the activity of SRrp53 in 3 splice site selection, in this
case, cooperating with the interacting proteins SF2/ASF,
SRp40, and U2AF35.
In summary, we present here the functional characterization
of a novel SR-related protein that is required for the second
step of pre-mRNA splicing and is also involved in alternative
splicing regulation.
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